SeaStar Medical Earnings Call Shows Growth Amid Risks

Seastar Medical Holding Corporation ((ICU)) has held its Q1 earnings call. Read on for the main highlights of the call.

SeaStar Medical Holding Corporation’s latest earnings call balanced optimism with caution as management highlighted rapid progress in both commercialization and clinical development. Revenue and cash expanded sharply year over year, margins remained exceptionally high and trial milestones advanced, yet the company remains small, unprofitable and exposed to regulatory and execution risks.

QUELIMMUNE Revenue Growth Signals Early Commercial Momentum

QUELIMMUNE net revenue reached $495,000 in Q1 2026, up nearly 70% from $293,000 a year earlier and reflecting stronger demand for the pediatric acute kidney injury therapy. Management cited continued order momentum into Q2 and reiterated an annual revenue goal of about $2.0 million for 2026, underscoring growing but still nascent commercialization.

Hospital Expansion Underscores Building Customer Traction

SeaStar added seven new hospitals in the quarter, bringing its customer count to roughly 17 centers using QUELIMMUNE. Executives emphasized repeat orders, rising clinical interest and the role of education and user forums in driving adoption, while aiming to sign about 15 new customers during 2026 to deepen market penetration.

NEUTRALIZE‑AKI Pivotal Trial Makes Steady Enrollment Progress

The NEUTRALIZE‑AKI pivotal study enrolled 198 of 339 planned patients, putting the program at roughly 58% completion. Management is targeting completion of enrollment around year‑end 2026, positioning the company to potentially deliver topline results by mid‑2027 if site activation and patient accrual stay on track.

SAVE Registry Completion Marks Key Safety Milestone

SeaStar completed enrollment of 50 patients in the SAVE Registry, providing a real‑world safety dataset for QUELIMMUNE in critically ill children. The company is now conducting 28‑day safety analyses and plans to ask regulators to convert the registry from mandatory to voluntary, which could reduce friction for hospitals and support broader adoption if accepted.

High Gross Margins Highlight Attractive Economic Profile

Gross profit margin exceeded 90% in Q1 2026, consistent with the prior three quarters and underscoring the high‑value profile of the company’s cartridge‑based therapy. Such margins suggest significant operating leverage potential if volumes grow, though current revenue levels remain modest and limit near‑term impact on profitability.

Strengthened Cash Position Enhances Liquidity Cushion

Cash stood at $9.3 million as of March 31, 2026, up from $5.2 million a year earlier, representing a roughly 79% increase in liquidity. Management argued that this stronger balance sheet provides better support for ongoing clinical trials and commercial rollout, even as the business continues to generate quarterly losses.

Expense Discipline and Narrowing Net Loss

Operating expenses were flat year over year at about $4.1 million, reflecting tight cost control despite advancing clinical programs. Net loss improved to approximately $3.5 million, or $0.90 per share, versus $3.8 million, or $4.38 per share, as a larger share base and stable spending helped temper per‑share losses.

Regulatory Strategy Centers on Accelerated Pathways

Management reported active engagement with regulators over a modular PMA submission and potential rapid approval routes, including reliance on existing special designations to speed adult acute kidney injury commercialization. Successful agreement on these pathways could materially accelerate time to market in adults, though outcomes remain uncertain and subject to ongoing review.

Limited Revenue Base Highlights Early‑Stage Risk

Despite impressive growth rates, the company’s commercial footprint is still small, with Q1 revenue of only $495,000 and a heavy reliance on ultra‑rare pediatric cases. This patient‑driven demand introduces volatility in order patterns and underscores that SeaStar remains early in its monetization curve despite encouraging hospital uptake.

Continued Losses and Rising R&D Spend Weigh on Outlook

SeaStar continues to post quarterly net losses near $3.5 million while funding its pivotal trial program and commercial expansion. Research and development spending is expected to rise roughly 5% each quarter through 2026, which could pressure the cash runway if revenue growth slows or market penetration lags expectations.

Enrollment Dependence on New Sites Adds Execution Risk

The NEUTRALIZE‑AKI study still needs about 141 additional patients to reach its 339‑patient goal, making timely enrollment a critical execution milestone. Management has activated new trial centers to accelerate accrual, but hitting the year‑end 2026 finish target depends on efficient site ramp‑up and adequate patient flow, leaving room for potential slippage.

Regulatory Outcomes and ICU Integration May Temper Adoption

The company’s plans to use modular submissions, obtain faster approval routes and shift the registry to voluntary status are all subject to regulatory decision‑making. Third‑party feedback also suggests that integrating QUELIMMUNE into intensive care workflows is not trivial, which could slow adoption even where supportive renal replacement therapy protocols exist.

Significant Share Dilution Clouds Equity Appeal

Weighted average shares outstanding surged from about 862,000 in Q1 2025 to roughly 3.9 million in Q1 2026, a jump of more than 350%. While this dilution helped reduce per‑share losses, it also materially diluted existing investors and may limit near‑term upside for equity holders absent outsized commercial or clinical catalysts.

Forward‑Looking Guidance Emphasizes Growth and Discipline

SeaStar reaffirmed its 2026 plans to drive pediatric QUELIMMUNE sales toward approximately $2.0 million, add about 15 new hospital customers and complete NEUTRALIZE‑AKI enrollment by year‑end with potential topline data in mid‑2027. Management also guided to gross margins above 90%, stable general and administrative costs, modest quarterly R&D increases and continued focus on preserving cash while advancing key clinical and regulatory milestones.

SeaStar’s earnings call painted a picture of a company moving steadily from concept toward commercialization, with strong percentage growth, high margins and meaningful clinical progress. Yet investors must weigh these positives against persistent losses, a very small revenue base, dilution and regulatory and enrollment risks that will likely drive the stock’s risk‑reward profile over the next two years.